London · Delayed Price · Currency is GBP · Price in GBX EKF Diagnostics Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Resilient H1 2026 results featured flat revenue at GBP 25 million, improved margins, and 26% EPS growth. Strong order book and operational progress support confidence in a robust H2 and full-year outlook, with ongoing investments and strategic rebranding initiatives.
Fiscal Year 2025
-
Revenue rose 3% to GBP 51.6m with gross margin up to 51% and EBITDA at GBP 12.4m. Strategic execution in 2025 included portfolio simplification, strong growth in LATAM and BHB, and a GBP 5m share buyback. Outlook targets operational excellence, new product launches, and continued expansion.
-
Revenue and profit remained stable year-over-year, with gross margin improving to 50% and EBITDA up 7.4%. Strategic investments in production and Life Sciences, new contracts in growth markets, and a continued share buyback support long-term growth targets.
Fiscal Year 2024
-
Revenue reached £50.2M with gross margin up to 48% and adjusted EBITDA at £11.3M. Strong cash generation supports a five-year plan targeting £80M+ revenue and £20M+ EBITDA by 2029, with growth focused on haemoglobin, fermentation, and BHB.